SGCB and hydrops fetalis: According to the findings of studies that used the fixed-effect model, the sGC modulators significantly improved EQ-5D based quality of life in patients with HF (MD = 0.03, 95% CI 0.02–0.04, p < 0.001), without significant heterogeneity in three trials (I2 = 42%, p = 0.18) (Fig. 4).